DNA METHYLATION BIOMARKERS FOR DETECTION OF HIGH-GRADE DYSPLASIA AND ESOPHAGEAL OR JUNCTIONAL ADENOCARCINOMA
Methods and kits to distinguish normal or Barrett's esophageal samples from high grade dysplasia (HGD), esophageal adenocarcinoma (EAC), or junctional adenocarcinoma (JCA) samples are described. The methods and kits utilize the methylation status of epigenetic markers, such as cg6522, POU3F1, YPEL3, and/or MAFB.
1 . A method to test a subject for the presence of high grade dysplasia (HGD), esophageal adenocarcinoma (EAC), or junctional adenocarcinoma (JCA) in the subject, the method comprising:
obtaining a tissue sample derived from the subject;
detecting a methylation status of cytosines located in epigenetic loci consisting of cg6522 and POU3F1 from the tissue sample to generate a methylation value;
and
determining that high grade dysplasia (HGD), esophageal adenocarcinoma (EAC), or junctional adenocarcinoma (JCA) is present or absent in the subject based on the generated methylation value.
2 . A method to test a subject for the presence of high grade dysplasia (HGD), esophageal adenocarcinoma (EAC), or junctional adenocarcinoma (JCA) in the subject, the method comprising:
obtaining a tissue sample derived from the subject;
detecting a methylation status of cytosines located in epigenetic loci consisting of cg6522, POU3F1, YPEL3, and MAFB from the tissue sample to generate a methylation value;
and
determining that high grade dysplasia (HGD), esophageal adenocarcinoma (EAC), or junctional adenocarcinoma (JCA) is present or absent in the subject based on the generated methylation value.
3 . A method to test a subject for the presence of high grade dysplasia (HGD), esophageal adenocarcinoma (EAC), or junctional adenocarcinoma (JCA) in the subject, the method comprising:
obtaining a tissue sample derived from the subject;
detecting a methylation status of cytosines located in an epigenetic loci selected from cg6522, POU3F1, YPEL3, and/or MAFB from the tissue sample to generate a methylation value;
and
determining that high grade dysplasia (HGD), esophageal adenocarcinoma (EAC), or junctional adenocarcinoma (JCA) is present or absent in the subject based on the generated methylation value.
4 . The method of claim 3 , wherein the generated methylation value is increased in comparison to a reference level; the HGD, EAC, or JCA is present; and the subject is diagnosed with the HGD, EAC, or JCA.
5 . The method of claim 3 , wherein the generated methylation value is not increased in comparison to a reference level and the HGD, EAC, or JCA is not present.
6 . A method to diagnose a subject as having (i) a normal or Barrett's esophagus tissue sample or (ii) a high grade dysplasia (HGD), esophageal adenocarcinoma (EAC), or junctional adenocarcinoma (JCA) tissue sample, the method comprising:
obtaining a tissue sample derived from the subject;
detecting a methylation status of cytosines located in an epigenetic loci selected from cg6522, POU3F1, YPEL3, and/or MAFB from the tissue sample to generate a methylation value;
and
diagnosing the subject as having (i) normal or Barrett's esophagus or (ii) HGD, EAC, or JCA based on the generated methylation score.
7 . The method of claim 6 , wherein the subject is diagnosed as having normal or Barrett's esophagus when the generated methylation value is not increased over a reference level.
8 . The method of claim 6 , wherein the subject is diagnosed as having HGD, EAC, or JCA when the generated methylation value is increased over a reference level.
9 . The method of claim 4, 5, 7, or 8 , wherein the reference level is derived from a population of subjects having normal or Barrett's esophagus.
10 . The method of claim 3 or 6 , wherein the epigenetic loci comprise or consist of (i) cg6522, POU3F1, and YPEL3; or (ii) cg6522, POU3F1, YPEL3, and MAFB.
11 . The method of claim 3 or 6 , wherein the epigenetic loci comprise or consist of cg6522 and POU3F1.
12 . The method of claim 3 or 6 , wherein the tissue sample was obtained with an esophageal brush or sponge.
13 . The method of claim 4 or 8 , wherein the diagnosing with HGD, EAC, or JCA directs an aggressive or experimental treatment for the subject.
14 . The method of claim 4 or 8 , wherein the diagnosing with HGD, EAC, or JCA directs radiofrequency ablation (RFA) and intramucosal resection (EMR).
15 . The method of claim 7 , wherein the diagnosing with normal or Barrett's esophagus directs monitoring the patient with additional esophageal screenings over time.
16 . The method of claim 7 , wherein the diagnosing with normal or Barrett's esophagus directs moderate, minimal, or no treatment.
17 . The method of claim 3 or 6 , wherein the detecting comprises extracting genomic DNA from cells.
18 . The method of claim 17 , wherein the extracted genomic DNA comprises 4 ng of DNA.
19 . The method of claim 3 or 6 , wherein the detecting comprises treating extracted genomic DNA with bisulfite.
20 . The method of claim 3 or 6 , wherein the detecting comprises performing methylation-specific PCR on bisulfite treated DNA.
21 . The method of claim 3 or 6 , wherein the detecting comprises partitioning bisulfite treated DNA into partitions.
22 . The method of claim 21 , wherein the partitions are water-in-oil droplets.
23 . The method of claim 21 , wherein each partition contains one or zero fragments of bisulfite treated DNA.
24 . The method of claim 21 , wherein each partition comprises an amplification mixture.
25 . The method of claim 24 , wherein the amplification mixture comprises at least one primer or primer pair, at least one probe, at least one replication enzyme, and deoxynucleotide and/or nucleotide triphosphates.
26 . The method of claim 25 , wherein the at least one primer pair has the sequences as set forth in SEQ ID NOs: 9 and 10 or sequences having at least 95% sequence identity thereto.
27 . The method of claim 26 , wherein the at least one probe has the sequence as set forth in SEQ ID NO: 11 or a sequence having at least 95% sequence identity thereto.
28 . The method of claim 25 , wherein the at least one primer pair has the sequences as set forth in SEQ ID NOs: 12 and 13 or sequences having at least 95% sequence identity thereto.
29 . The method of claim 28 , wherein the at least one probe has the sequence as set forth in SEQ ID NO: 14 or a sequence having at least 95% sequence identity thereto.
30 . The method of claim 25 , wherein the at least one primer pair has the sequences as set forth in SEQ ID NOs: 15 and 16 or sequences having at least 95% sequence identity thereto.
31 . The method of claim 30 , wherein the at least one probe has the sequence as set forth in SEQ ID NO: 17 or a sequence having at least 95% sequence identity thereto.
32 . The method of claim 25 , wherein the at least one primer pair has the sequences as set forth in SEQ ID NOs: 9, 10, 15, and 16, or sequences having at least 95% sequence identity thereto.
33 . The method of claim 32 , wherein the at least one probe has the sequence as set forth in SEQ ID NOs: 11 and 17 or sequences having at least 95% sequence identity thereto.
34 . The method of claim 25 , wherein the at least one primer pair has the sequences as set forth in SEQ ID NOs: 9, 10, 12, 13, 15, and 16, or sequences having at least 95% sequence identity thereto.
35 . The method of claim 32 , wherein the at least one probe has the sequence as set forth in SEQ ID NOs: 11, 14, and 17 or sequences having at least 95% sequence identity thereto.
36 . The method of claim 25 , further comprising thermocycling the partitions to perform PCR.
37 . The method of claim 36 , further comprising analyzing partitions for the presence of PCR-positive partitions.
38 . A kit for distinguishing (i) a normal or Barrett's esophagus tissue sample from (ii) a high grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), or junctional adenocarcinoma (JCA) tissue sample, the kit comprising reagents to detect methylation status of cytosines located in one or more epigenetic loci selected from cg6522, POU3F1, YPEL3, and/or MAFB.
39 . The kit of claim 38 , wherein the reagents detect methylation status of cytosines within (i) cg6522, POU3F1, and YPEL3; or (ii) cg6522, POU3F1, YPEL3, and MAFB.
40 . The kit of claim 38 , wherein the reagents detect methylation status of cytosines within cg6522 and POU3F1.
41 . The kit of claim 38 , wherein the kit comprises a primer pair having the sequences as set forth in SEQ ID NOs: 9 and 10 or sequences having at least 95% sequence identity thereto.
42 . The kit of claim 41 , wherein the kit comprises a probe that has the sequence as set forth in SEQ ID NO: 11 or a sequence having at least 95% sequence identity thereto.
43 . The kit of claim 38 , wherein the kit comprises a primer pair having the sequences as set forth in SEQ ID NOs: 12 and 13 or sequences having at least 95% sequence identity thereto.
44 . The kit of claim 43 , wherein the kit comprises a probe that has the sequence as set forth in SEQ ID NO: 14 or a sequence having at least 95% sequence identity thereto.
45 . The kit of claim 38 , wherein the kit comprises a primer pair having the sequences as set forth in SEQ ID NOs: 15 and 16 or sequences having at least 95% sequence identity thereto.
46 . The kit of claim 45 , wherein the kit comprises a probe that has the sequence as set forth in SEQ ID NO: 17 or a sequence having at least 95% sequence identity thereto.
47 . The kit of claim 38 , wherein the kit comprises primer pairs having the sequences as set forth in SEQ ID NOs: 9, 10, 15, and 16, or sequences having at least 95% sequence identity thereto.
48 . The kit of claim 47 , wherein the kit comprises probes that have the sequence as set forth in SEQ ID NOs: 11 and 17 or sequences having at least 95% sequence identity thereto.
49 . The kit of claim 38 , wherein the kit comprises primer pairs having the sequences as set forth in SEQ ID NOs: 9, 10, 12, 13, 15, and 16, or sequences having at least 95% sequence identity thereto.
50 . The kit of claim 49 , wherein the kit comprises probes that have the sequence as set forth in SEQ ID NOs: 11, 14, and 17 or sequences having at least 95% sequence identity thereto.
51 . The kit of claim 38 , further comprising DNA-fragmenting enzymes.
52 . The kit of claim 38 , further comprising bisulfite.
53 . The kit of claim 38 , further comprising a replication enzyme.
54 . The kit of claim 53 , wherein the replication enzyme is a thermostable polymerase.
55 . The kit of claim 38 , further comprising and deoxynucleotide and/or nucleotide triphosphates
56 . The kit of claim 38 , further comprising a reference level.
57 . The kit of claim 56 , wherein the reference level is derived from a population of subjects with normal or Barrett's esophagus.
58 . The kit of claim 57 , wherein an increased methylation value as compared to the reference level distinguishes the sample as HGD, EAC, or JCA.
59 . The kit of claim 38 , further comprising a detectable label.
60 . The kit of claim 59 , wherein the detectable label is a radioactive isotope, enzyme, dye, magnetic bead, or biotin.
61 . The kit of claim 60 , wherein the dye is a fluorescent dye.
62 . A method of surveilling a Barrett's esophagus patient for the development of HGD, EAC, or JCA comprising repeatedly
obtaining a tissue sample derived from the patient;
detecting a methylation status of cytosines located in an epigenetic loci selected from cg6522, POU3F1, YPEL3, and/or MAFB from the tissue sample to generate a methylation value;
and
diagnosing the subject as having (i) Barrett's esophagus or (ii) HGD, EAC, or JCA based on the generated methylation score.
63 . The method of claim 62 , wherein the surveilling includes repeating the steps of claim 60 every 3 months to 3 years depending on each patient's condition.
64 . The method of claim 62 , further comprising treating the patient for HGD, EAC, or JCA when the subject is diagnosed with HGD, EAC, or JCA.
65 . The method of claim 64 , wherein the treating comprises radiofrequency ablation (RFA) and intramucosal resection (EMR).